Skip to main
IFRX

InflaRx (IFRX) Stock Forecast & Price Target

InflaRx (IFRX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

InflaRx is a clinical-stage biotechnology company developing anti-inflammatory therapeutics targeting C5a/C5aR complement pathway. With its lead candidate, izicopan, expected to effectively replace the now impaired Tavneos (avacopan) as the standard-of-care in ANCA-associated vasculitis, and promising data for other indications, the company has a strong pipeline. Additionally, with Gohibic (vilobelimab) already approved for emergency/exceptional treatment of COVID, InflaRx has the potential for near-term revenue generation.

Bears say

InflaRx is facing significant challenges in the development of their product candidates, as proven by the multiple indications still being studied in proof of concept trials. Furthermore, the proposed Phase 3 trial for their candidate, izicopan, may change its primary endpoints based on Phase 2 data and interactions with the FDA. In addition, potential hepatotoxicity and concerns about the drug's efficacy in treating autoimmune diseases raise concerns about its commercial potential. With these uncertainties and risks, the financial outlook for InflaRx appears negative.

InflaRx (IFRX) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InflaRx (IFRX) Forecast

Analysts have given InflaRx (IFRX) a Buy based on their latest research and market trends.

According to 6 analysts, InflaRx (IFRX) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InflaRx (IFRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.